Eleftha 375 mg Injection
  1. Home
  2. Pharma Products
  3. Intas Pharmaceuticals Ltd
  4. Eleftha 375 mg Injection

Eleftha 375 mg Injection

Eleftha 375 mg Injection contains trastuzumab 375 mg, a targeted monoclonal antibody used in cancer treatment. It is used mainly for HER2-positive breast cancer and certain HER2-positive stomach cancers. The injection is administered by a qualified healthcare professional under medical supervision.

BUY NOW

Category

Trastuzumab targets the HER2 protein on cancer cells and helps block signals responsible for their growth and survival. It may be used alone or with chemotherapy and other medicines depending on the patient’s cancer and treatment plan. Regular monitoring is important during therapy because trastuzumab can cause infusion-related reactions and may affect heart function. The dosage and treatment schedule are determined by the oncologist based on HER2 status, cancer type, and clinical response.

Technical Specification

Specification Details
Active Ingredient Trastuzumab
Strength 375 mg
Dosage Form Injection
Route of Administration Intravenous Infusion
Pack Size 1 Vial
Manufacturer/Marketer Intas Pharmaceuticals Ltd

Product Also Known As

Eleftha 375mg Injection, Eleftha 375 mg Vial, Eleftha 375 Injection, Trastuzumab 375mg Injection, Trastuzumab 375 mg Injection, Trastuzumab 375mg Vial, HER2 Targeted Therapy Injection